Skip to main content

Table 2 Toxicity and supportive care - incidence of severe toxicity among treated patients.

From: A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study

  Group A (CP)
N= 89
Group B (CLD)
N= 84
  Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
Neutropenia 14 (16) 20 (22) 18 (20) 9 (10) 13 (15) 20 (24) 23 (27) 7 (8)
Anaemia 29 (33) 0 (0) 3 (3) 0 (0) 27 (32) 23 (27) 7 (8) 1 (1)
Leucopenia 24 (27) 23 (26) 5 (6) 1 (1) 25 (30) 30 4 (5) 1 (1)
Thrombocytopenia† 1 (1) 6 (7) 2 (2) 0 (0) 4 (5) 7 (8) 9 (10) 1 (1)
Stomatitis   1 (1)   0 (0) 7 (8) 5 (6) 3 (3) 0 (0)
Nausea/vomiting 18 (20) 10 (11) 1 (1) 0 (0) 16 (19) 12 (14) 4 (5) 0 (0)
Diarrhoea 5 (6) 1 (1) 1 (1) 0 (0) 5 (6) 1 (1) 0 (0) 0 (0)
Infection 1 (1) 3 (3)   0 (0) 3 (4) 1 81) 1 (1) 1 (1)
Neurotoxicity‡ 24 (27) 27 (30) 5 (6) 1 (1) 19 (12) 1 (1) 0 (0) 0 (0)
Alopecia‡ 1 (1) 56 (63) 18 (20) 0 (0) 12 (14) 5 (6) 4 (5) 0 (0)
Allergy 18 (20) 9 (10) 1 (1) 0 (0) 4 (5) 2 (2) 1 (1) 0 (0)
Skin 6 (7) 2 (2) 0 (0) 0 (0) 9 (11) 12 (14) 1 (1) 0 (0)
Hand and foot 0 (0) 0 (0) 0 (0) 0 (0) 2 (2) 8 (10) 0 (0) 0 (0)
Fatigue 12 (13) 6 (7) 0 (0) 0 (0) 8 (10) 6 (7) 0 (0) 0 (0)
Fever   5 (6) 0 (0) 0 (0) 2 (2) 4 (5) 0 (0) 0 (0)
Anorexia 4 (4) 2 (2) 0 (0) 0 (0) 5 (6)   0 (0) 0 (0)
Cardiac 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0)
Arthralgias/myalgias 18 (20) 8 (9) 0 (0) 0 (0) 6 (7) 0 (0) 0 (0) 0 (0)
  1. †Rate of severe thrombocytopenia is higher among patients treated with CLD (group B) (11% versus 2%, p = 0.016)
  2. ‡Rates of severe neurotoxicity and alopecia are higher among patients treated in group A (CP; 7% versus 0%, P = 0.029 and 20% versus 5%, P = 0.003)